Clinical Trials Logo

Spondylarthritis clinical trials

View clinical trials related to Spondylarthritis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05206591 Withdrawn - Clinical trials for Active Peripheral Spondyloarthritis (pSpA)

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

CAIN457X12301
Start date: August 16, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of subcutaneous (s.c) secukinumab in comparison with placebo for participants with two subtypes of active pSpA i.e. undifferentiated pSpA and chronic reactive arthritis, and with an inadequate response to conventional therapy despite current or previous Non-steroidal Anti Inflammatory Drugs (NSAIDs) and/or csDMARDs. Additionally, the study aims to evaluate efficacy and safety of continuing versus withdrawing secukinumab therapy in maintaining remission in the study population.

NCT ID: NCT05119712 Withdrawn - Clinical trials for Ankylosing Spondylitis

Terbinafine Treatment of Axial Spondyloarthropathy

FUN
Start date: March 9, 2021
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to determine if further research is warranted to assess if anti-fungal therapy is an effective adjunctive treatment for axial spondyloarthropathy

NCT ID: NCT04315090 Withdrawn - Spinal Stenosis Clinical Trials

Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion

Start date: October 9, 2020
Phase:
Study type: Observational

This research study is being conducted to help improve the pre-operative, intra-operative, and post-operative course for patients and enhance recovery.

NCT ID: NCT02429882 Withdrawn - Clinical trials for Axial Spondyloarthritis

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of brodalumab compared with placebo in participants with axial spondyloarthritis. Subjects will be randomized in a 1:1 ratio to brodalumab or placebo for the first part of the study. Subjects will then receive open label brodalumab for the remainder of the study. The entire study will be 312 weeks in duration for each subject.

NCT ID: NCT00972218 Withdrawn - Crohn's Disease Clinical Trials

Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

Start date: July 2009
Phase: Phase 4
Study type: Interventional

Adalimumab is an antibody treatment that targets and neutralizes a molecule produced in the body that is associated with inflammation, tumor necrosis factor (TNF). This molecule is an important factor in causing the inflammation seen in people with a form of inflammatory spinal arthritis called spondylitis as well as inflammation in the bowel called Crohn's disease. Spondylitis and Crohn's disease tend to go together and this study will assess to what degree this treatment is effective for those patients that have both disorders at the same time.

NCT ID: NCT00298012 Withdrawn - Clinical trials for Spondylitis, Ankylosing

Methotrexate in the Treatment of Axial Spondyloarthritis

Start date: March 2006
Phase: Phase 4
Study type: Interventional

The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.